S6 Kinase Deletion Suppresses Muscle Growth Adaptations to Nutrient Availability by Activating AMP Kinase  by Aguilar, Victor et al.
Cell Metabolism
ArticleS6 Kinase Deletion Suppresses Muscle
Growth Adaptations to Nutrient Availability
by Activating AMP Kinase
Victor Aguilar,1,2,12 Samira Alliouachene,1,2,12 Athanassia Sotiropoulos,1,2,12 Andrew Sobering,1,2 Yoni Athea,3,4
Fatima Djouadi,5 Sylvain Miraux,6 Eric Thiaudie`re,6 Marc Foretz,7,8 Benoit Viollet,7,8 Philippe Diolez,6
Jean Bastin,5 Paule Benit,9 Pierre Rustin,9 David Carling,10 Marco Sandri,11 Rene´e Ventura-Clapier,3,4
and Mario Pende1,2,*
1 INSERM, U845, Paris F-75015, France
2 Universite´ Paris Descartes, UMRS-845, Paris F-75015, France
3 INSERM, U769, Chaˆtenay-Malabry F-92296, France
4 Universite´ Paris-Sud, Faculte´ de Pharmacie, IFR141, Chaˆtenay-Malabry F-92296, France
5 CNRS, UPR 9078, Universite´ Paris Descartes, Paris F-75015, France
6 CNRS, UMR 5536, Bordeaux F-33076, France
7 INSERM, U567, Paris F-75014
8 Institut Cochin, Universite´ Paris Descartes, CNRS, UMR 8104, Paris F-75014, France
9 INSERM, U676, Paris F-75019, France
10 Cellular Stress Group, MRC Clinical Sciences Centre, Imperial College, Hammersmith Hospital, London W12 0NN, UK
11 Dulbecco Telethon Institute at the Venetian Institute of Molecular Medicine, Department of Biomedical Science,
University of Padova, Padova 35129, Italy
12 These authors contributed equally to this work.
*Correspondence: pende@necker.fr
DOI 10.1016/j.cmet.2007.05.006SUMMARY
S6 kinase (S6K) deletion in metazoans causes
small cell size, insulin hypersensitivity, and
metabolic adaptations; however, the underlying
molecular mechanisms are unclear. Here we
show that S6K-deficient skeletal muscle cells
have increased AMP and inorganic phosphate
levels relative to ATP and phosphocreatine,
causing AMP-activated protein kinase (AMPK)
upregulation. Energy stress and muscle cell
atrophy are specifically triggered by the S6K1
deletion, independent of S6K2 activity. Two
known AMPK-dependent functions, mitochon-
drial biogenesis and fatty acid b-oxidation, are
upregulated inS6K-deficient muscle cells, lead-
ing to a sharp depletion of lipid content, while
glycogen stores are spared. Strikingly, AMPK
inhibition in S6K-deficient cells restores cell
growth and sensitivity to nutrient signals. These
data indicate that S6K1 controls the energy
state of the cell and the AMPK-dependent met-
abolic program, providing a mechanism for cell
mass accumulation under high-calorie diet.
INTRODUCTION
In mammals, S6 kinases 1 and 2 (S6K1/2) are serine/
threonine kinases that transduce the anabolic signals
from nutrition (Um et al., 2006). Insulin, insulin-like growth476 Cell Metabolism 5, 476–487, June 2007 ª2007 Elsevier Infactor (IGF) peptides, glucose, and amino acids initiate in-
tracellular pathways that converge on the activation of the
mammalian target of rapamycin (mTOR) complex, a key
event in the regulation of S6K (Sarbassov et al., 2005).
Growth-factor peptides control mTOR/S6K via class 1a
phosphatidylinositol 3-kinase (PI3K), Akt kinases, the tu-
berous sclerosis complex proteins 1 and 2 (TSC1/2), and
the small GTPase Rheb, while nutrients require class 3
PI3K (Nobukuni et al., 2005). In addition, nutrient availabil-
ity indirectly controls mTOR/S6K by altering the energy
status of the cell. High ATP levels increase the catalytic
activity of mTOR (Dennis et al., 2001), while the AMP/
ATP ratio modulates AMP-activated protein kinase
(AMPK). In turn, AMPK controls the activity of TSC2 and
inhibits mTOR signaling (Krause et al., 2002; Inoki et al.,
2003).
That S6K is involved in sensing nutrient availability and
mediating growth responses is suggested by the pheno-
type of S6K mutant animals. S6K null flies are develop-
mentally delayed and small due to a reduction of cell size
(Montagne et al., 1999). Similarly, S6K1-deficient mice
have an approximately 20% reduction in body weight as
compared to wild-type mice (Shima et al., 1998). The
growth defect is more pronounced in nutrient- and insu-
lin/IGF-target tissues such as pancreatic b cells, skeletal
muscle, and adipose tissue, where the size of mutant cells
is sharply reduced (Pende et al., 2000; Um et al., 2004;
Ohanna et al., 2005). In many regards, the S6K1 deletion
mimics the metabolic adaptations to a low-calorie diet.
Glucose-stimulated insulin secretion and blood insulin
levels are low in these mice (Pende et al., 2000), while
lipolysis is increased (Um et al., 2004). In addition,c.
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AMPK Activation in S6K Null CellsS6K/ skeletal muscle mass is refractory to starvation
and is equivalent to starved wild-type mice (Ohanna
et al., 2005). Finally, on a high-fat diet, S6K1-deficient
mice do not become obese (Um et al., 2004).
How S6K1 exerts its anabolic action is unclear. One
possibility is that it upregulates protein synthesis by phos-
phorylating ribosomal protein S6 (rpS6), initiation factor
eIF4B, elongation factor 2 kinase (eEF2K), or other sub-
strates involved in translational control (Sarbassov et al.,
2005). Consistent with this possibility, S6K1 associates
with a translation preinitiation complex in a growth-factor-
and nutrient-dependent manner (Holz et al., 2005). How-
ever, S6K2 can rescue rpS6 phosphorylation but cannot
compensate for the growth defect due to S6K1 deletion,
indicating that ribosomal phosphorylation does not corre-
late with the growth state of the cell (Ohanna et al., 2005).
Moreover, the combined deletion of S6K1 and S6K2
(S6K1;S6K2/) in fibroblasts and embryonic stem cells
does not affect global translation initiation, as assessed
by the polysome/monosome ratio, or the translation of
specific classes of mRNAs under the control of the
mTOR pathway, such as the 50-terminal oligopyrimidine
tract (50TOP) mRNAs (Pende et al., 2004). Thus, the mo-
lecular changes underlying the growth defects and meta-
bolic adaptations of S6K-deficient tissues remain unclear.
Since growth requires ATP, growth-factor pathways
have evolved molecular mechanisms to upregulate the
energy status of the cell (Hammerman et al., 2004). Partic-
ularly, the Akt kinases have pleiotropic effects on nutrient
uptake, glycolysis, and oxidative phosphorylation (Ed-
inger and Thompson, 2002; Majewski et al., 2004), leading
to increased high-energy phosphate levels that may acti-
vate the mTOR/S6K pathway (Hahn-Windgassen et al.,
2005). Here we address whether the S6K deletion affects
energy production. We find that S6K1;S6K2/ muscles
have an increased AMP/ATP ratio, causing AMPK activa-
tion. This response is also observed in other tissues and
depends on S6K1 activity. Finally, we provide evidence
that the AMPK activation contributes to the atrophic
adaptations of S6K1-deficient mice. We conclude that
the growth-regulating mTOR/S6K1 kinases control an
AMPK-dependent metabolic program.
RESULTS
Energy Stress in S6K-Deficient Mice
The deletion of S6K1 and S6K2 caused an 20% reduc-
tion of muscle cell diameter at the myotube stage
(Figure 1A; Ohanna et al., 2005). To address whether a de-
fect in energy production affects the size of cultured mus-
cle cells, wild-type and S6K1;S6K2/ cells were treated
with oligomycin and 2-deoxyglucose, which inhibit mito-
chondrial ATP synthase and glycolysis, respectively.
Wild-type cell size was significantly reduced by both
energy-depriving agents (Figure 1A). Conversely, S6K
mutant cells displayed a partial resistance. Moreover,
energy-deprived wild-type cells were comparable in size
to S6K-deficient cells. Thus, energy deprivation and S6KCedeletion affect muscle cell size through mechanisms that
might be partly shared.
To evaluate whether the S6K deletion alters the energy
state of skeletal muscle cells, we first assayed the adenine
nucleotide pools and phosphocreatine (PCr) in skeletal
muscle by enzymatic reactions. Strikingly, AMP levels
were increased by 40% in S6K1;S6K2/ muscles, while
total ATP levels did not differ from the control, leading to
a higher AMP/ATP ratio in mutant muscles. (Figure 1B).
Since the ATP concentration in skeletal muscle is kept rel-
atively constant by the creatine kinase reaction, we asked
whether a drop in phosphocreatine levels accompanied
the rise in AMP levels of S6K null muscles. Although a sta-
tistically significant difference was not reached, there was
a tendency toward a reduction of the PCr pool relative to
the ATP pool in mutant muscles (Figure 1B). To confirm
these data, 31P NMR quantitation of phosphorus metabo-
lites was performed in the gastrocnemius muscles of live
mice at rest. The AMP concentration was below detection
level by 31P NMR spectroscopy, though the 30% increase
in inorganic free phosphate (Pi) of S6K-deficient muscles
was consistent with mutant mice presenting a depletion
of high-energy phosphates (Figure 1C). Strikingly, the Pi
increase in S6K mutant muscles was accompanied by
an equivalent decrease of PCr levels. The mean values
of the phosphorus metabolites allowed an estimation of
the fall in the cytosolic free energy of ATP hydrolysis
(DGp) in the S6K mutant muscles (Figure 1C). In conclu-
sion, the combined deletion of S6K1 and S6K2 causes
a dissipation of available free energy in skeletal muscles.
To determine the adenine nucleotide levels in tissue
lacking the creatine/PCr system, we assayed ATP in livers
from mutant mice. As shown in Figure S1 in the Supple-
mental Data available with this article online, ATP levels
were reduced by 34% in S6K1;S6K2/ livers. Thus,
S6K deficiency causes a depletion of energy supplies in
the form of PCr in skeletal muscles and in the form of
ATP in other tissues such as liver.
Despite their high homology, S6K1 and S6K2 differ in
their ability to promote muscle cell growth and sensitivity
to environmental cues, as these responses depend on
S6K1 activity (Pende et al., 2000; Um et al., 2004; Ohanna
et al., 2005). Thus, we determined which gene deletion
triggered a state of energy deprivation in muscle. The de-
letion of S6K1 was sufficient to increase the AMP/ATP ra-
tio, while the S6K2-deficient muscles did not differ as
compared to the wild-type (Figure 1D). Taken together,
these data indicate that the atrophic state of the S6K
mutant mice correlates with a decrease in high-energy
phosphate levels.
S6K Deletion Sensitizes Cells to AMPK Action
The concentration of adenine nucleotides tightly regulates
the balance between anabolic and catabolic processes
(Atkinson, 1970), in part through the activation of AMPK
during energy stress and increased AMP/ATP ratio
(Kahn et al., 2005). The heterotrimeric AMPK complex,
consisting of a catalytic subunit (a) and two regulatory
subunits (b and g), has multiple substrates that arell Metabolism 5, 476–487, June 2007 ª2007 Elsevier Inc. 477
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AMPK Activation in S6K Null CellsFigure 1. Energy Stress in S6K1-
Deficient Skeletal Muscles
(A) Cells were allowed to differentiate for 2 days
in 2% horse serum and then incubated for
2 days in the presence or absence of 20 nM
oligomycin (Oligom) or 20 mM 2-deoxyglucose
(2DOG). Myotube diameter was measured at
day 4 of differentiation. Histograms show re-
sults for at least three assays. Independent
cell cultures were obtained from at least two
mice of the indicated genotype. *p < 0.05
versus wild-type control. Oligomycin- or 2DOG-
treated S6K1;S6K2/ cells were not signifi-
cantly different from untreated mutant cells.
In this and all other figures, error bars represent
±SEM.
(B) Metabolites were extracted from hindlimb
muscles of the indicated genotype. Histo-
grams are means from at least four mice. *p <
0.05 versus wild-type genotype.
(C) In vivo energy phosphate levels were as-
sessed in hindlimb muscles by 31P NMR.
n R 8 mice. *p < 0.05 versus wild-type geno-
type.
(D) Energy phosphate levels were assessed by
enzymatic procedure as in (B). *p < 0.05 versus
wild-type genotype; #p < 0.05 versus S6K1
genotype.involved in reprogramming sugar, fat, and protein metab-
olism. Since S6K-deficient muscles had a higher AMP/
ATP ratio, we evaluated AMPK activity in these cells by im-
munoblot analysis against phospho-Thr172 AMPKa. Of
note, the basal phosphorylation of AMPK was approxi-
mately 3-fold higher in S6K-deficient myotube cultures
as compared to wild-type (Figures 2A and 2B). In addition,
AMPK phosphorylation in mutant muscle cells displayed
higher sensitivity to increasing doses of oligomycin (Fig-
ure 2A). Thus, the shutdown of the S6K pathway in muscle
cells upregulates AMPK activity. Importantly, AMPK acti-
vation is observed in a pure population of S6K-deficient
muscle cells, suggesting that this regulation does not
involve humoral factors and is a likely consequence of in-
creased intracellular AMP concentration, the allosteric
regulator of AMPK.
To evaluate the functional consequence of AMPK acti-
vation, we assessed the phosphorylation of the AMPK
substrate acetyl-CoA carboxylase (ACC), the enzyme
that catalyzes the conversion of acetyl-CoA to malonyl-
CoA in the cytosol (Kahn et al., 2005). Malonyl-CoA is an
intermediate in fatty acid synthesis and an allosteric inhib-
itor of carnitine palmitoyltransferase 1, which regulates the
transfer of long-chain acyl-CoAs from the cytosol into the
mitochondria. The AMPK-mediated phosphorylation of
ACC decreases enzyme activity, resulting in increased ox-
idation of long-chain acyl-CoAs. ACC phosphorylation478 Cell Metabolism 5, 476–487, June 2007 ª2007 Elsevier Incwas stimulated in S6K1;S6K2/ cells, consistent with
the AMPK upregulation (Figure 2C, lanes 1 and 2). In addi-
tion, S6K1;S6K2/ myotubes displayed a sharp reduc-
tion of total ACC levels similar to that observed in cells ex-
pressing a constitutively active AMPK allele (Foretz et al.,
2005). Thus, in S6K1;S6K2/ myotubes, the relative
amount of active unphosphorylated ACC is decreased
due to the coordinated effect on AMPK-mediated ACC
phosphorylation and expression.
AMPK is the molecular target of the antidiabetic drug
metformin, which improves glucose homeostasis and in-
sulin sensitivity (Kahn et al., 2005). A 2 day treatment of
wild-type myotubes with metformin increased AMPK ac-
tivity while reducing S6K and 4EBP-1 phosphorylation,
consistent with the reported action of AMPK on TSC2
(Figure 2D). However, the inhibition of the mTOR pathway
by metformin was partial, as indicated by the residual
phosphorylation of both mTOR substrates and of rpS6.
Conversely, the macrolide rapamycin sharply inhibited
mTORC1 signaling, as judged by the absence of detect-
able S6K and rpS6 phosphorylation. In addition this
long-term incubation of myotubes with rapamycin also
decreased the phosphorylation of the mTORC2 substrate
Akt, possibly as a consequence of reduced mTORC2
complex formation (Sarbassov et al., 2006). mTOR down-
regulation by rapamycin was sufficient to increase the
AMP/ATP ratio by 87% in cultured myotubes (AMP/ATP.
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AMPK Activation in S6K Null CellsFigure 2. AMPK Activation in S6K-Deficient Muscle Cells
(A) Immunoblot analysis of protein extracts from myotubes of the indicated genotype using anti-phospho-Thr172 AMPKa and anti-AMPKa anti-
bodies. Cells were allowed to differentiate for 4 days and were treated for 30 min with oligomycin (2 to 200 nM). Ratio of phospho-AMPKa to total
AMPKa signal intensity is indicated.
(B) Average of phospho-AMPKa to total AMPKa ratios from three distinct cultures in basal conditions.
(C and D) Immunoblot analysis of protein extracts from myotubes using the indicated antibodies. Muscle cells were allowed to differentiate for 2 days
and were transduced with GFP or kd-AMPK adenoviruses at the indicated moi (C) or were treated with 0.25 mM metformin or 20 nM rapamycin (D).
Cell lysates were prepared 2 days later.
(E) Immunoblot analysis of protein extracts from myotubes using the indicated antibodies. Cells were transfected with 20 nM control or S6K siRNA at
day 1 of differentiation and harvested 3 days later. The lower panel shows the average myotube diameter from three distinct experiments.ratio of 0.08 ± 0.01 in untreated myotube cells at day 4 of
differentiation and 0.15 ± 0.02 after a 2 day treatment with
rapamycin). Interestingly, the combination of rapamycin
and metformin cooperated in stimulating AMPK phos-
phorylation, suggesting that mTOR inhibition can potenti-
ate metformin action on AMPK. Similarly, the stimulatory
effect of metformin on AMPK was more pronounced in
S6K1;S6K2/ myotubes, suggesting that the complete
inactivation of S6K genes sensitizes the cells to the
AMPK-activating agents. As previously reported (Um
et al., 2004), S6K1;S6K2/ cells also presented an upre-
gulation of Akt activity (Figure 2D). Thus, S6K deletion
ameliorates both AMPK and Akt signaling, two major
pathways in the control of nutrient homeostasis.
To address whether a transient inactivation of S6K sig-
naling is sufficient to upregulate the AMPK pathway inCmuscle cells, wild-type myotube cultures were trans-
fected with small interfering RNA (siRNA) targeting both
S6K1 and S6K2 mRNAs. Although the siRNA effectively
reduced S6K expression, the impact on rpS6 phosphory-
lation was minor, possibly due to residual kinase activity
(Figure 2E). However, this decrease in S6K expression
was sufficient to upregulate AMPK activity and concomi-
tantly affect cell growth. Thus, the effects on AMPK activ-
ity and cell size are early events after the shutdown of S6K
signaling.
Next we addressed which S6K gene affects AMPK sig-
naling. Consistent with the effect on AMP levels (Fig-
ure 1D), S6K1 deletion was sufficient to increase AMPK
phosphorylation to the same extent as the combined de-
letion of S6K1 and S6K2 genes (Figure S2). Importantly,
this effect correlated with myotube atrophy.ell Metabolism 5, 476–487, June 2007 ª2007 Elsevier Inc. 479
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AMPK Activation in S6K Null CellsFigure 3. Whole-Body Increased Sensitivity to AMPK Activation in S6K-Deficient Mice
(A and B) Immunoblot analysis of protein extracts from hepatocytes (A) or adipose tissue (B) of the indicated genotype using anti-phospho-Thr172
AMPKa and anti-AMPKa antibodies. Hepatocytes were treated for 30 min with oligomycin (2 to 2000 nM). Epididymal fat pads from three different
mice for each genotype were analyzed.
(C and D) AICAR tolerance test was performed by intraperitoneal injection of 0.15 g AICAR per kg body weight into overnight-fasted 5-month-old
mice. Basal glucose levels for wild-type and S6K1;S6K2/ mice were 80.7 ± 3.4 and 72.7 ± 3.9 mg/dl, respectively (C). Basal glucose levels for
wild-type, S6K1/, and S6K2/ mice were 111.8 ± 6.7, 109.5 ± 4.7, and 107.8 ± 9.4 mg/dl, respectively (D). n = 6–15; *p < 0.05 versus wild-
type group.To determine whether AMPK control by S6K is specific
to muscle cells, we extended our analysis to liver and fat
tissues. As shown in Figure 3A, primary hepatocytes
from S6K-deficient mice also had higher basal and oligo-
mycin-induced AMPK activation as compared to wild-
type. Similarly, S6K1;S6K2/ epididymal fat pads from
randomly fed mice displayed increased phosphorylation
of AMPK (Figure 3B). In addition, S6K-deficient fat tissues
presented higher levels of Akt phosphorylation. Thus, the
deletion of S6K causes a general activation of the AMPK
pathway in multiple tissues, and in a cell-autonomous
manner. Of note, this effect is concomitant with an upre-
gulation of the insulin/Akt anabolic pathway.
To evaluate whether the S6K deletion is sufficient to af-
fect AMPK-dependent whole-body glucose homeostasis,
blood glucose was assayed after an intraperitoneal injec-
tion of the cell-permeable AMPK activator 5-aminoimida-
zole-4-carboxamide ribonucleoside (AICAR). As shown in
Figure 3C, AICAR caused a 30% reduction in blood glu-
cose levels of wild-type mice, possibly due to the com-
bined effects on muscle glucose uptake activation and he-
patic glucose output inhibition (Mu et al., 2001). Strikingly,
the hypoglycemic effect of AICAR was more pronounced480 Cell Metabolism 5, 476–487, June 2007 ª2007 Elsevier Inc.in S6K1;S6K2/ mice. In addition, the single deletion of
S6K1 was sufficient to induce higher sensitivity to AICAR,
while the inactivation of S6K2 had no effect (Figure 3D).
Thus, the differential sensitivity to AMPK activation de-
pends on S6K1 expression and has functional conse-
quences on glucose homeostasis in the animal.
Energy Metabolism Is Altered by S6K Deletion
To gain further insights into the functional significance of
AMPK activation at the cellular level, we evaluated mito-
chondrial enzyme activities inS6K1;S6K2/ muscle cells.
Mitochondria are the main site of substrate oxidation
within the cell, and their biogenesis is upregulated by the
AMPK pathway (Zong et al., 2002). The activity of two mi-
tochondrial enzymes, citrate synthase and cytochrome c
oxidase, was increased by 50%–70% in S6K1;S6K2/
myotubes (Figures 4A and 4B), while the activity of the gly-
colytic enzyme hexokinase did not differ as compared to
wild-type control (Figure 4C). Mitochondrial fatty acid box-
idation, a major target of AMPK regulation (Kahn et al.,
2005), was also augmented in mutant muscle cell cultures,
as measured by [3H]palmitate oxidation (Figure 4D). Fur-
thermore, these functional changes were accompanied
Cell Metabolism
AMPK Activation in S6K Null CellsFigure 4. Increased Mitochondrial Mass
and Activity in S6K-Deficient Muscle
Fibers Is Accompanied by Lipid Content
Depletion and Glycogen Sparing
(A–C) Assessment of citrate synthase, cyto-
chrome c oxidase, and hexokinase was per-
formed in cells at day 4 of differentiation.
(D) Fatty acid b-oxidation was measured in
myoblast cells maintained in complete medium
for 2 days. (n R 3 assays.) Independent cell
cultures were obtained from at least three
mice of the indicated genotype.
(E) Total RNA was isolated from muscle cells
allowed to differentiate for 4 days in 2% horse
serum. Gene expression levels were quantified
by RT-qPCR. (nR 3 assays.) Independent cell
cultures were obtained from at least two mice
of the indicated genotype.
(F and G) Hindlimb muscles from 7–11 mice of
the indicated genotype were pooled, and gly-
cogen (F) and lipid (G) content was measured.
n = 3 pools of the indicated genotype; *p < 0.01
versus wild-type genotype.by the upregulation of mRNAs encoding the PPARg tran-
scriptional coactivator 1a (PGC-1a) and the mitochondrial
transcription factor A (TFAM) (Figure 4E), two factors re-
quired for mitochondrial biogenesis (Wu et al., 1999), while
hexokinase mRNA levels were unchanged. In addition, the
expression of the uncoupling protein-2 (UCP2) gene,
a PGC-1a target that may affect proton leak from mito-
chondria (Wu et al., 1999), was increased in mutant myo-
tubes. As previously reported for S6K1/ white adipose
tissue and plantaris muscle (Um et al., 2004), we observed
an increased mitochondrial mass by electron microscopy
in cultured S6K1;S6K2/ myotubes (data not shown).
In conclusion, S6K deletion leads to a cell-autonomous
upregulation of mitochondrial mass, activity, and b-
oxidation.
To measure the regulation of mitochondrial substrate
utilization by phosphate acceptors, we evaluated the
ADP dependency of respiration rates in permeabilized
fibers from gastrocnemius and soleus muscles. As ex-
pected, the utilization of glutamate and malate substrates
was more pronounced in the oxidative slow-twitch soleus
muscles as compared to the glycolytic fast-twitch gas-
trocnemius (Figure S3). In both muscle types, the respira-
tion rate independent of ADP phosphorylation (V0) was in-
creased in S6K1;S6K2/ fibers, suggesting a state of
energy expenditure and increased basal metabolism.
The maximal respiration rate in the presence of saturating
ADP levels (Vmax) was also increased in S6K1;S6K2
/
fibers. Therefore, the coupling ratio, as defined by the
Vmax/ V0 ratio (ACR), was not significantly different among
the two genotypes and did not reveal uncoupling defectsCin permeabilized mutant fibers under controlled extramito-
chondrial medium and energy substrates.
The two major energy sources in skeletal muscles are
glycogen and lipids. Since we observed increased fatty
acid oxidation in S6K-deficient myotubes, we quantified
the nature of energy stores in muscle. The glycogen
amount was more abundant in S6K1;S6K2/ gastrocne-
mius as compared to wild-type, while the total lipid con-
tent was reduced by half (Figures 4F and 4G). Thus, the
S6K deletion promotes the sparing of glycogen accompa-
nied by a shift toward mitochondrial fatty acid oxidation,
possibly due to the concomitant increase in mitochondrial
biogenesis and downregulation of ACC. These metabolic
adaptations recapitulate a state of increased AMPK
signaling, as observed in prolonged fasting or endurance
exercise (Kahn et al., 2005).
AMPK Inhibition Rescues S6K/ Cell Growth
To address whether the increased AMPK activity is impli-
cated in the growth defect of S6K-deficient muscle cells,
we overexpressed by adenovirus-mediated gene transfer
a mutant form of AMPKa2 carrying a K45R substitution.
This kinase-dead mutant (kd-AMPK) induces the partial
degradation of endogenous AMPKa subunits and acts
as a dominant-inhibitory allele (Mu et al., 2001). A slower
migrating AMPK immunoreactive band corresponding to
the myc-tagged mutant was observed in kd-AMPK-
expressing myotubes as compared to GFP-transduced
control cells (Figure 2C). kd-AMPK decreased the expres-
sion of the endogenous AMPKa subunit, resulting in theell Metabolism 5, 476–487, June 2007 ª2007 Elsevier Inc. 481
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AMPK Activation in S6K Null CellsFigure 5. AMPK Inhibition Partially
Rescues Cell Size
(A and B) Cells of the indicated genotype were
allowed to differentiate for 2 days and were
transduced with 150 moi GFP, 150 moi con-
stitutively active Akt (MyrAkt), or kd-AMPK
adenoviruses at the indicated moi. Where indi-
cated, cells were then treated with 20 nM rapa-
mycin (R) or cultured in amino acid-free
medium (Aa). After 2 days, myotube diameter
was measured and expressed as percentage
change over GFP-transduced cells of the
appropriate genotype. Representative bright-
field images are shown in (A). Data from two
to five experiments are shown in histograms
in (B).
(C) Immunoblot analysis of protein extracts
from myotubes using the indicated antibodies.
Cells were transfected with 20 nM control or
AMPK siRNA at day 1 of differentiation and
harvested 3 days later. The lower panel shows
the average myotube diameter from two dis-
tinct experiments.
(D) Tibialis anterior muscles were coelectro-
porated with kd-AMPK and GFP cDNAs, the
latter as a marker of transfection. Fiber cross-
sectional area in transfected and untrans-
fected fibers was measured. Representative
bright-field images are shown in the upper
panel. n = 2–6 muscles in histograms in lower
panel; *p% 0.05 versus untransfected fibers.inhibition of ACC phosphorylation and the increase of total
ACC expression. Conversely, kd-AMPK promoted mTOR
signaling, as indicated by the increased phosphorylation
of 4EBP-1 and S6K1. Next, the effect on myotube size
was measured 48 hr after transduction. As previously
reported (Ohanna et al., 2005), the size of S6K-deficient
myotubes was smaller (6.2 ± 0.2 mm diameter for GFP-
expressing S6K1;S6K2/ muscle cells versus 8.9 ± 0.5
for wild-type cells) and was completely resistant to the in-
hibitory effects of rapamycin or amino acid starvation (Fig-
ures 5A and 5B), demonstrating that S6K inactivation
mimics an atrophic status triggered by nutrient/mTOR de-
pletion. The hypertrophic action of constitutively active
Akt1 (MyrAkt) in wild-type cells was mediated by rapamy-
cin-sensitive and -insensitive pathways, as previously ob-482 Cell Metabolism 5, 476–487, June 2007 ª2007 Elsevier Incserved (Rommel et al., 2001; Ohanna et al., 2005). Rapa-
mycin treatment or amino acid deprivation had no effect
on MyrAkt-induced cell growth in S6K1;S6K2/ myo-
tubes, indicating that the mTOR-independent branch is
the only mechanism operating in these cells. kd-AMPK ex-
pression led to a dose-dependent growth of both wild-
type and S6K1;S6K2/ cells. The size of S6K1/ cells
was comparable to double mutants (Ohanna et al., 2005;
Figure S2) and was also rescued by kd-AMPK expression
(Figure 5B). In addition, an RNAi targeting both a1 and a2
catalytic subunits of AMPK reproduced the effect of kd-
AMPK expression on cell size of wild-type and mutant
S6K genotypes (Figure 5C). Taken together, these data
demonstrate that AMPK activity contributes to the size
control of muscle cells..
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AMPK Activation in S6K Null CellsStrikingly, AMPK inhibition not only rescued the atrophy
of S6K1;S6K2/ cells but also conferred sensitivity to the
activation of the nutrient/mTOR pathway, as rapamycin
and amino acid starvation blunted growth of kd-AMPK-
expressing S6K1;S6K2/ cells (Figure 5B). The inhibition
by rapamycin was approximately 70% at the kd-AMPK
dose of 300 moi, suggesting that mTORC1-dependent
and -independent pathways promote cell growth when
S6K is deleted and AMPK is inhibited.
To extend our findings in vivo, we electroporated kd-
AMPK and GFP cDNAs in the tibialis anterior muscles of
wild-type and S6K1;S6K2/ mice. Twelve days after
electroporation, mice were either starved for 48 hr or al-
lowed free access to food. As shown in Figure 5D, in
wild-type mice, starvation reduced the cross-sectional
area (CSA) of untransfected fibers by 25%, though the
S6K1;S6K2/ fiber size was completely resistant to
food deprivation. Of note, the kd-AMPK-transfected fibers
in wild-type and in S6K1;S6K2/ muscles were 27% and
57% larger, respectively, as compared to untransfected
fibers. In addition, their growth was dependent on food in-
take. In conclusion, we demonstrate that the energy stress
triggered by S6K1 deletion upregulates the AMPK path-
way, which in turn switches on a starvation-like metabolic
program and arrests growth. Inhibition of this AMPK-
dependent response allows cell mass accumulation in
response to nutrient availability.
DISCUSSION
The energy charge of the adenine nucleotide pool is the
universal coupling agent of metabolism, providing the
directionality toward the synthesis or the degradation of
cellular constituents (Atkinson, 1970). Metazoans have
developed a complex signal transduction network that co-
ordinates the energy status of the cell with extracellular
growth factors and nutrient availability to regulate growth
rates. In this study, we show that the suppression of nutri-
ent-activated mTOR/S6K1 signaling is sufficient to trigger
an energy stress response that is coordinated by AMPK.
This AMPK-dependent metabolic program blunts the
growth responses to nutrient availability and thereby plays
a central role in the atrophic phenotype of S6K1-deficient
animals.
The crosstalk between S6K and AMPK is emerging as
a powerful and highly regulated way to gauge cellular en-
ergy and nutrition content leading to changes in growth
and metabolic rates. In skeletal muscles, the AMPK mod-
ule predominates during low-calorie diet and endurance
exercise, while the S6K module is turned on during high-
calorie diet and resistance exercise (Atherton et al.,
2005; Um et al., 2004). It was previously shown that
AMPK downregulates mTOR/S6K signaling via TSC2
phosphorylation (Inoki et al., 2003). Here we provide evi-
dence that the reverse regulation also takes place in the
cell, as S6K signaling controls AMPK by affecting the
AMP/ATP ratio (Figure 1 and Figure 2). This tight control
probably serves the important function of enforcing the
unidirectionality of metabolic sequences during a particu-Celar energy status and avoiding futile cycles in which syn-
thesis and degradation are simultaneously turned on.
Due to these counterregulatory mechanisms, S6K dele-
tion leads to opposite traits as compared to the inhibition
of AMPK signaling in skeletal muscles. The expression of
a kinase-dead form of AMPK or the inactivation of the
muscle-specific AMPKg3 subunit causes a decrease in
PGC-1a expression, a defect in mitochondrial biogenesis
and in glycogen synthesis, and a slight increase in fiber
size (Mu et al., 2001; Zong et al., 2002; Mu et al., 2003;
Nilsson et al., 2006; Krawiec et al., 2007), while S6K/
muscle fibers have small size (Figure 1 and Figure 5) and
increased glycogen content, mitochondrial mass, and
enzymatic activities that are accompanied by the upregu-
lation of PGC-1a and TFAM (Figure 4). When the kinase-
dead AMPK mutant is introduced in S6K-deficient muscle
cells, the defect in cell growth is rescued (Figure 5), sug-
gesting that the AMPK-dependent metabolic program is
a downstream target of the S6K pathway and contributes
to the phenotype of S6K-deficient muscles.
Of note, AMPK inhibition renders S6K1;S6K2/ cell
growth sensitive to nutrient availability and mTOR activity,
suggesting that additional rapamycin-sensitive mTOR
substrates regulate muscle growth when AMPK is in-
hibited (Figure 5). These may include the eIF4E-binding
proteins that are hyperphosphorylated in cells expressing
a dominant-inhibitory form of AMPK (Figure 2C). Addi-
tional molecular mechanisms that regulate protein synthe-
sis and ribosome biogenesis downstream of mTOR and
independent of S6K activity (Pende et al., 2004) are likely
to participate in muscle growth when the inhibitory action
of AMPK is relieved. Thus, we propose that S6K activity
sensitizes skeletal muscle cells to growth factors and
nutrients through AMPK regulation rather than directly af-
fecting cell growth. Although no known physiological con-
dition displays inactive S6K while mTORC1 is active, the
genetic inactivation of S6K unveils this molecular mecha-
nism that may become clinically relevant when selective
S6K inhibitors are developed. Interestingly, environmental
signals mainly affect growth of glycolytic muscle fibers
while sparing oxidative fibers, as observed during ca-
chexia- or malnutrition-induced atrophy (Mendell and En-
gel, 1971). Since S6K-deficient muscle cells display in-
creased oxidative metabolism and resistance to nutrient
levels, it is possible that the S6K-AMPK gauge determines
muscle plasticity to environmental cues by altering the gly-
colytic-oxidative properties.
Our study sheds light on the S6K-dependent utilization
of glucose and fatty acids, the two major energy sources
in skeletal muscles. By a series of biochemical and gene
expression analyses, we have established that S6K-defi-
cient muscles preferentially use fatty acids rather than glu-
cose, leading to a sharp difference in lipid and glycogen
content as compared to wild-type (Figure 4). This re-
sponse is typically observed in muscles after long-term
starvation or endurance exercise (Jagoe et al., 2002), pos-
sibly involving AMPK-PGC-1a-mediated mechanisms
(Atherton et al., 2005). How does the suppression of
S6K1 signaling in skeletal muscle affect the energy chargell Metabolism 5, 476–487, June 2007 ª2007 Elsevier Inc. 483
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cific energy substrates are limiting in S6K-deficient mus-
cles in vivo, e.g., due to the suppression of specific uptake
systems. Although an exhaustive list of uptake systems
was not analyzed in this study, our data failed to uncover
a defect in the uptake of glucose, system A substrates, or
the complete amino acid mixture in isolated muscle (data
not shown; Pende et al., 2000). To analyze the processes
of intracellular nutrient utilization, we next evaluated mito-
chondrial respiration, the main energy-producing system.
When the mitochondria from S6K-deficient muscle fibers
were provided with glutamate and malate substrates in a
controlled medium, no functional uncoupling of the
respiratory chain was revealed (Figure S3). Since these
studies were conducted in permeabilized fibers, we can-
not rule out the possibility that specific energy substrates
or decoupling agents are affecting oxidative phosphoryla-
tion in vivo. However, our data favor the possibility of an
increased energy expenditure state that is triggered by
S6K inactivation. Interestingly, a number of conditions ap-
pear to reproduce a similar metabolic program in skeletal
muscle. Stimulation by adiponectin (Civitarese et al.,
2006) or CNTF (Watt et al., 2006), sirtuin activation by re-
sveratrol (Baur et al., 2006), and stearoyl-CoA desaturase
deficiency (Dobrzyn et al., 2004) also alter the energy
balance and activate AMPK, suggesting novel crosstalk
between these factors and the mTOR/S6K signaling.
S6K1 is emerging as a key factor promoting cell mass
accumulation in response to nutrition and downregulating
insulin action in adipose tissue and skeletal muscles (Um
et al., 2004; Ohanna et al., 2005). Consistent with this,
S6K1 is hyperactive in animal models of obesity (Um
et al., 2004). However, little is known about its mechanism
of action. The phosphorylation of translation factors or IRS
proteins has been put forward to explain S6K1 effects on
growth or insulin sensitivity, though direct evidence is
lacking. Our results indicate that the suppression of
S6K1 activity simultaneously promotes AMPK and Akt
signaling (Figure 2), thus ameliorating metformin and insu-
lin action, which represent two major diabetes therapies.
In conclusion, the control of energy charge and AMPK
activity by S6K1 contributes to glucose homeostasis and
muscle plasticity, providing a molecular mechanism that




Generation of S6K-deficient mice has been previously described
(Shima et al., 1998; Pende et al., 2004). AICAR tolerance tests were
performed in the morning by intraperitoneal injection of 0.15 g AICAR
(Biomol) per kg body weight into overnight-fasted mice. Blood was
collected from the tail vein at 0, 15, 30, 45, and 100 min after injection
for determination of glucose levels by Glucotrend glucometer (Roche
Diagnostics).
Cell Cultures
Primary muscle cell cultures were derived from gastrocnemius and ti-
bialis anterior muscles of 4-week-old mice as described (Ohanna et al.,
2005). Primary hepatocytes were prepared as described (Pende et al.,484 Cell Metabolism 5, 476–487, June 2007 ª2007 Elsevier In2004). To measure the effect of ectopic gene expression on size, my-
otubes at day 2 of differentiation were transduced by kd-AMPK (kindly
provided by M.J. Birnbaum, University of Pennsylvania School of Med-
icine), GFP, or MyrAkt adenovirus at the indicated moi and incubated
for 2 days in DMEM/Ham’s F12 medium + 2% horse serum. When in-
dicated, transduced cells were treated with 20 nM rapamycin or grown
in amino acid-free DMEM + 2% dialyzed horse serum for 2 days. For
RNA interference against S6K and AMPK, 21-nucleotide siRNA du-
plexes with two deoxythymidine bases as 30 overhangs were synthe-
sized corresponding to S6K1/2 target sequence (50-CTCAGTGA
GAGTGCCAACCAA-30), AMPKa1/a2 target sequence (50-AAGAGA
AGCAGAAGCACGACG-30 ), and control (50-AAGCCGGTATGCCGGT
TAAGT-30 ). Myotubes at day 1 of differentiation were transfected
with 20 nM siRNA using HiPerFect (QIAGEN). Cells were harvested
3 days after transfection. Bright-field images were taken of live cells
and analyzed using Lucia archive software. The diameter of at least
400 myotubes was measured in a region where myonuclei were absent
and diameter was constant.
Immunoblotting
For immunoblot analysis, cells were washed twice with cold phos-
phate-buffered saline (PBS), scraped off of the culture dish in lysis
buffer B (50 mM Tris [pH 8.0], 1% NP-40, 120 mM NaCl, 20 mM
NaF, 1 mM benzamidine, 1 mM EDTA, 1 mM EGTA, 15 mM sodium
pyrophosphate, 1 mM PMSF, 2 mM sodium orthovanadate, 2 mg/ml
leupeptin, 5 mg/ml aprotinin, 1 mg/ml pepstatin A), and sonicated for
30 s. Adipose tissue was lysed in 20 mM Tris-HCl (pH 8.0), 5% glycerol,
138 mM NaCl, 2.7 mM KCl, 1% NP-40, 20 mM NaF, 5 mM EDTA, 1 mM
sodium orthovanadate, 5 mg/ml leupeptin, 1 mg/ml pepstatin, 1 mM
DTT. To remove cell debris, homogenates were spun at 8000 3 g for
10 min at 4C. Protein extract was resolved by SDS-PAGE before
transfer onto nitrocellulose membrane and incubation with the follow-
ing primary antibodies: anti-phospho-Thr389 S6K1, anti-phospho-
Thr172 AMPKa, anti-AMPKa, anti-phospho-Ser79 ACC, anti-ACC,
anti-phospho-Ser473 Akt, anti-Akt, anti-4EBP-1, anti-phospho-
Ser65 4EBP-1 (Cell Signaling), monoclonal anti-S6K2 (kindly provided
by G. Thomas, University of Cincinnati), anti-a-tubulin (TU-02, Santa
Cruz), anti-MAPK (Upstate Biotechnology). To estimate the levels
of phosphorylation of AMPK, Akt, and S6K reported relative to total
protein or tubulin, densitometry was performed using ImageJ software
(http://rsb.info.nih.gov/ij/).
Quantitative RT-PCR
Total RNA was prepared using TRIzol reagent according to the manu-
facturer’s protocol (Life Technologies), and single-strand cDNA was
synthesized from 400 ng of total RNA with random hexamer primers
and SuperScript II (Invitrogen). Real-time quantitative PCR (RT-
qPCR) was performed using a LightCycler instrument (Roche) accord-
ing to the manufacturer’s instructions using a SYBR Green I kit
(QIAGEN). Briefly, the final volume of 20 ml contained 16 ng of re-
verse-transcribed total RNA, 1 nM of primer mix, 10 ml of 23 SYBR
Green PCR mix. Reactions were carried out in capillaries (Roche)
with 40 cycles. We determined the relative amounts of the mRNAs
studied by means of the second-derivative maximum method, with
LightCycler analysis software version 3.5 and b-actin as the invariant
control for all studies. RT-qPCR primers were designed using se-
quences available in PrimerBank and spanned an intron/exon bound-
ary. The murine primer sequences used were peroxisome proliferator-
activated receptor a (PGC-1a) sense 50-GGAATGCACCGTAAATCT
GC-30, antisense 50-TTCTCAAGAGCAGCGAAAGC-30; hexokinase II
(HKII) sense 50-TGATCGCCTGCTTATTCACGG-30, antisense 50-AAC
CGCCTAGAAATCTCCAGA-30; b-actin sense 50-CTGGCTCCTAG
CACCAAGAT-30, antisense 50-GGTGGACAGTGAGGCCAGGAT-30;
mitochondrial transcription factor A (TFAM) sense 50-GGAATGT
GGAGCGTGCTAAAA-30, antisense 50-ACAAGACTGATAGACGAGG
GG-30; UCP2 sense 50-ACTTTCCCTCTGGATACCGC-30, antisense
50-ACGGAGGCAAAGCTCATCTG-30. The results of RT-qPCR arec.
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Biochemical Studies
For enzymatic activities, myotube cell cultures were washed and
quickly frozen in liquid nitrogen. Cells were scraped off of the culture
dish and homogenized into ice-cold buffer containing 5 mM HEPES,
1 mM EGTA, 5 mM MgCl2, 1 mM dithiothreitol, 0.1% Triton X-100
(pH 8.7) and incubated for 60 min at 0C to ensure complete enzyme
extraction. Citrate synthase, hexokinase, and cytochrome c oxidase
were assessed by standard spectrophotometric methods (Srere,
1969; Bergmeyer et al., 1974).
For adenine nucleotides and PCr assays, mice were anesthetized by
intraperitoneal injection of 5% Rompun and 20% Imalgene 1000. Liver
and hindlimb muscles comprising gastrocnemius, soleus, and planta-
ris were quickly removed using cold forceps and snap frozen in liquid
nitrogen. Metabolites were extracted with perchloric acid, and ATP,
AMP, and PCr were measured in neutralized supernatant by coupled
enzyme assays (Bergmeyer, 1974).
For adenine nucleotide measurement in cell cultures, 6 cm plates
with myotubes at day 4 of differentiation were washed twice with
PBS and scraped in perchloric acid to a final concentration of 5%
(wt/vol). Acid-insoluble material was removed by centrifugation, and
perchloric acid was extracted from the supernatant by three washes
with 10% excess (by volume) of a 1:1 mixture of tri-n-octylamine and
1,1,2-trichlorotrifluoroethane. Nucleotides were separated by ion-
exchange chromatography on a Mono Q PC1.6/5 column run on
a SMART System (Amersham Biosciences) as described elsewhere
(Fryer et al., 2002). Nucleotides were detected by their absorbance
at 254 nm and compared with the elution position of standards. Areas
under the AMP and ATP peaks were quantified by integration using
SMART System software and used to calculate the AMP/ATP ratios.
For lipid and glycogen content, frozen tissue samples were ground
in liquid nitrogen, yielding a homogeneous tissue powder that was di-
vided in two aliquots. One aliquot was dried by lyophilization. The lipids
of freeze-dried powders were extracted by petrol ether. Lipid-free
powder was dried and used for determination of DNA contents by a di-
phenylamine assay (Forsberg et al., 1991). The other aliquot was used
for enzymatic analysis of glycogen after perchloric acid extraction
(Bergmeyer, 1974).
The respiratory parameters of the total mitochondrial population
were studied in situ in saponin-skinned fibers using a method de-
scribed earlier (Veksler et al., 1995). Briefly, respiratory rates were de-
termined using a Clark electrode in an oxygraphic cell at 22C with
continuous stirring. Thin muscle fibers were isolated in skinning (S)
solution containing (in mmol/l) 2.77 CaK2 EGTA, 7.23 K2 EGTA, 6.56
MgCl2, 5.7 Na2 ATP, 15 PCr, 20 taurine, 0.5 DTT, 50 K methanesulfo-
nate, 20 imidazole (pH 7.1) and incubated for 30 min in S solution with
50 mg/ml saponin. Permeabilized fibers were transferred to respiration
(R) solution (composition as S solution, but containing 3 mmol/l
K2HPO4 instead of PCr and ATP) for 10 min to wash out adenine nucle-
otides and PCr. All steps were carried out at 4C with continuous stir-
ring. Respiration rates of 10–15 mg of skinned fibers were measured at
22C in 3 ml of R solution containing 2 mg/ml bovine serum albumin
with 5 mM glutamate and 2 mM malate as substrates. Sensitivity to
ADP was determined by measuring respiration rates with increasing
levels of ADP. ADP-stimulated respiration (VADP) above basal oxygen
consumption (V0) was plotted as a function of [ADP]. VADP was calcu-
lated using a nonlinear fitting of the Michaelis-Menten equation. Max-
imal respiration rate (Vmax) was VADP + V0. Acceptor control ratio (ACR)
was calculated as Vmax/V0. After the experiment, fiber bundles were
dried and weighed. Rates of respiration are given in mmol O2/min/g
dry weight.
NMR Measurements
31P NMR of mouse gastrocnemius was carried out using a Bruker Bio-
spec 47/50 operating at 4.7 T equipped with a 12 cm gradient insert.
For this purpose, a 1.5 cm diameter Helmholtz transmit/receive radio-Cfrequency (RF) coil tuned at 81 MHz was designed in order to ensure
a correct localization of the NMR signal. Mice were anesthetized
with isoflurane (1.5% in air) and positioned prone in the magnet. The
RF coil was placed around both mouse hindlimbs. Proton shimming
was performed in order to reach a linewidth at half-height of typically
40 Hz for the water resonance. 31P NMR spectra (100 ms RF pulse,
2.8 s interpulse delay, 2048 data points, 1024 free induction decays,
15 Hz Lorentzian filter before Fourier transformation) were acquired
within 47 min. Spectra were then analyzed as a sum of Lorentzian-
Gaussian lineshaped resonances in order to determine the areas of
the nucleoside triphosphate (NTP) and the PCr resonances. The PCr,
Pi, and b-ATP peak areas were calculated and converted to concentra-
tions with [ATP] = 8.2 mmol/l (Kushmerick et al., 1993). Free energy of
ATP hydrolysis (DGp) was calculated as DG0 + RT ln([ADP][Pi][H+]/
[ATP]), where DG0 = 9.742 kJ/mol, at 37C, derived from Gibbs free
energy of hydrolysis under standard conditions at pH = 7.
Palmitate Oxidation
Fatty acid oxidation was measured by quantifying the production of
3H2O from [9,10-
3H]palmitate. The satellite cells were trypsinized,
counted, plated at 4 3 104 cells per well in 24-well gelatin-coated
culture plates, and allowed to grow for 2 days. Tritiated water release
experiments were performed in quadruplicate. Cultured muscle cells
were washed three times with Dulbecco’s PBS. Then, 200 ml of
[9,10(n)-3H]palmitic acid (60 Ci/mmol, NEN) bound to fatty-acid-free
albumin (final concentration 125 mM) containing 1 mM carnitine was
added per well. After 2 hr incubation at 37C, the mixture was removed
and added to a tube containing 200 ml of cold 10% trichloroacetic acid
(TCA). The tubes were centrifuged for 10 min at 2200 3 g at 4C, and
aliquots of supernatants (350 ml) were removed, mixed with 55 ml of 6 M
NaOH, and applied to ion-exchange resin. The columns were washed
twice with 750 ml of water, and the eluates were counted. Cell protein
content was determined by the Lowry method. Palmitate oxidation
rates were expressed as nmol of [3H]palmitate oxidized per hr per
mg of cell protein (nmol [3H]FA/hr/mg protein).
In Vivo Transfection Experiments and Fiber Size Measurements
Experiments were performed in 3-month-old mice. In vivo transfection
of tibialis anterior muscles was performed by intramuscular injection of
plasmids carrying myc-tagged kd-AMPK and GFP cDNAs followed by
electroporation as described (Sandri et al., 2004). Muscles were
removed at 14 days after transfection and frozen in liquid nitrogen
for fiber size measurements. Mice were either randomly fed or fasted
48 hr before sacrifice. Muscle fiber size was measured in fibers trans-
fected with the kd-AMPK mutant using GFP staining as a probe and in
an equal number of untransfected fibers from the same muscle. Fiber
cross-sectional areas were measured using Image software (Scion
Corporation).
Supplemental Data
Supplemental Data include three figures and can be found with this
article online at http://www.cellmetabolism.org/cgi/content/full/5/6/
476/DC1/.
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